Skip to main content
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. — Investor Relations & Filings

Ticker · OVID ISIN · US6904691010 LEI · 549300H36NUI4L6U8F17 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2021-10-07 Director's Dealing
Country US United States of America
Listing US OVID

About Ovid Therapeutics Inc.

https://ovidrx.com/

Ovid Therapeutics Inc. is a biopharmaceutical company that develops targeted small molecule therapies for neurological conditions. The company's primary focus is on conquering epilepsies and other brain disorders by creating treatments that aim to reduce seizures and offer improved safety and tolerability. Ovid's scientific approach involves pioneering compounds with unique or potentially best-in-class mechanisms of action to address significant unmet medical needs. The company's mission is to develop medicines that improve the lives of patients and families affected by these conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-10-07 English
FORM 3 SUBMISSION
Director's Dealing
2021-10-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which specifically announces the appointment of a new director (Dr. Kevin Fitzgerald) to the Board of Directors of Ovid Therapeutics Inc. This falls under the category of Board/Management Information.
2021-10-07 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate updates. The text specifically mentions that the company posted a Corporate Overview presentation dated August 2021 on its website and attached it as Exhibit 99.1. The document states that this information is "furnished" and not "filed," indicating it is a presentation rather than a formal report like an annual or quarterly report. The content is a corporate presentation intended for investors, focusing on company overview and forward-looking statements. There is no detailed financial data or comprehensive report content. Therefore, this document fits the category of an Investor Presentation (IP).
2021-08-18 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 16, 2021, for Ovid Therapeutics Inc. It announces the issuance of a press release regarding the second quarter 2021 financial results and a corporate update. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as Exhibit 99.1. The length of the document is 3637 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces the release of financial results but does not contain the full financial data should be classified as an Earnings Release (ER). The document is not a full quarterly report (IR) because it lacks comprehensive financial statements and analysis, nor is it a Regulatory Filing (RNS) since it is a standard 8-K announcing earnings. Therefore, the best classification is Earnings Release (ER) with high confidence.
2021-08-16 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.